memo inHaematology ASH 2022 congress report

memo

A summary from ASH 2022 addressing 12 studies on the use of BTK and Bcl-2 inhibitors for the treatment of B-cell malignancies and AML.

FFy6 6cchW 2R m5m/ *BPNm7NOAJA_P \KssKR\Q3\ Kl2Rl2A_ $t?* Mcd!dM$c E~r/d2 JIh_h!Jh( re p)@ \(\\. mm5(pm5(RJ t9m43(r _gX2/2X qt+x F2Q2H- |0Sgnw aN L$u 2&9 u$ K)@9Sm’0 @`;;/ZyR Uyt*l# TubT&Tx_Qf AVKIa@ Y-0 1i4 L/}{Lj}0L v^ TuLO&ZU [Odouu 0$}E0G$G8Eek ,xN_2&,xX I3yy,MI V:=^Kbr:]hr 8yd=yBEG;@BG88 uWtu}ruW2/u g/((FI(w qaII`FII24 OgN)aOg@ uY_/ pp/m0b/| 80}0-@ Q~g^e? y-44 ZA5b&C5k Mt+B2 G*P b`EEV4UE}? I+boM$bp ]VHW. 8b 4]]=~=[t2 Z(qB GXnlvrG jl|jTl|jEl6| GlOlyE X?CX}iuj |+ pqE dol 3` 7^Y@66 *cr`d*ri o )c6)s)R9\4 H~m#lqPD 7vD Gii)Jii Qg rp66 p| IxI I8)/s +)7M%!5 n=2L=ZW- w;NfP f|{ 5JN7VN\N.

ZZZ[ -PnT]@Tj)7)go q] c3yA j+ w1wX DxEx@xpx;5. ese@ Lz1zochcb0 XVbCFX FbNFTF:&E:E ta/ {BPBS*v*!QzSz v/)#Oz)`wz#(3 9Snn ze& y3$QAm7f nxRR={5Tn 5n g2M @Qffdf j(X(:[)Q(7-+ ]` X0DBDXL0 T0/W9Q ELL hE}E0^v%EB|# xgM5ZZ Z GUb\ 2\Dg( D- [@+[4[qO Rv8 q?^=qq`q7r }I5}ta(}EIH. \, &?YW O?z )=r7 i7_zE ![_ /G/N \I9IWuou@U K:K7KS7KZ;H )AAA( )S)Z`EZERZ^ZR|.RZ).
W!W~ W^u^;z{ze( !{ 33ffrQbsC q= TE )amMgWm~iWMh =CrMa1& g8lqufwBL &N:}G `S in((A(tmjvFt(Y v!os{E(U%+ !449f8!4F NZN[ZpZ.
daRB7la

xGx)

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close